LIXT LIXTE BIOTECHNOLOGY HOLDING...

Nasdaq lixte.com


$ 4.52 $ 0.20 (4.62 %)    

Tuesday, 21-Oct-2025 16:32:48 EDT
QQQ $ 610.75 $ -0.16 (-0.03 %)
DIA $ 469.29 $ 2.20 (0.47 %)
SPY $ 671.35 $ -0.01 (0 %)
TLT $ 91.98 $ 0.45 (0.49 %)
GLD $ 379.24 $ -25.91 (-6.43 %)
$ 4.53
$ 4.25
$ 4.15 x 100
$ 4.67 x 35
$ 4.15 - $ 4.56
$ 0.64 - $ 6.26
136,318
na
20.66M
$ 0.64
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-24-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-19-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-09-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 03-29-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-10-2022 06-30-2022 10-Q
14 05-11-2022 03-31-2022 10-Q
15 03-21-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-10-2021 06-30-2021 10-Q
18 05-12-2021 03-31-2021 10-Q
19 03-26-2021 12-31-2020 10-K
20 11-10-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-11-2020 03-31-2020 10-Q
23 03-25-2020 12-31-2019 10-K
24 11-08-2019 09-30-2019 10-Q
25 08-06-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 03-25-2019 12-31-2018 10-K
28 11-08-2018 09-30-2018 10-Q
29 08-02-2018 06-30-2018 10-Q
30 04-27-2018 03-31-2018 10-Q
31 03-23-2018 12-31-2017 10-K
32 11-09-2017 09-30-2017 10-Q
33 08-04-2017 06-30-2017 10-Q
34 05-10-2017 03-31-2017 10-Q
35 03-29-2017 12-31-2016 10-K
36 11-04-2016 09-30-2016 10-Q
37 08-10-2016 06-30-2016 10-Q
38 05-06-2016 03-31-2016 10-Q
39 03-28-2016 12-31-2015 10-K
40 11-10-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 lixte-biotech-hldgs-q2-eps-029-up-from-045-yoy

Lixte Biotech Hldgs (NASDAQ:LIXT) reported quarterly losses of $(0.29) per share. This is a 35.56 percent increase over losses ...

 lixte-biotechnologys-lb100-highlighted-in-nature-study-showing-pp2a-inhibition-enhances-immunotherapy-response-in-ovarian-and-colorectal-cancers

Article Indicates that Inhibition of PP2A Enhances Immunotherapy Responsewith LIXTE's Proprietary Compound LB100PASADENA, C...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION